Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with mild cognitive impairment or mild dementia related to Alzheimer's disease
- People who score 11 or higher on a standard memory and thinking test called the MoCA
- People whose medications for mood, sleep, or memory have been at a stable dose (confirm with trial site)
Who may not be able to join:
- People who have a known allergy or sensitivity to fisetin (a natural compound found in some fruits and vegetables)
- People who have a medical condition or abnormal routine blood test results that the trial doctor believes could put them at risk or prevent them from completing the trial
- People who have unstable medical conditions
- People currently taking antibiotics or antifungal medications to treat an active infection
- People currently receiving treatment for cancer
- People with an active alcohol or substance use disorder
- People who have had recent active bleeding
- People taking blood thinners, anti-cancer medications, anti-seizure medications, or other medications that could interact significantly with fisetin
- People who have used senolytic supplements, antioxidant supplements, or certain natural health products within the past month (confirm with trial site for specific products)
- People who have another neurological or brain condition that affects memory or thinking
- People currently experiencing a major depressive episode, active thoughts of suicide, or psychosis
- People who are unable to have an MRI scan for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Krista Lanctôt, PhD, Sunnybrook Research Institute
Phone: 416-480-6100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.